Estrella Immunopharma, Inc. (ESLAW) stock

ESLAWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLA

Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.09+0.02 (+25.07%)

Close on Nov 13, 2026Market cap $22.36MP/E –Yield –

Estrella Immunopharma statistics

55 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Jun 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $22.36M; $272.32M
Enterprise Value: $22.26M; $146.23M

Share statisticsIndustry

Shares Outstanding: 43M; 58M
Float: 43M; 49M
Shares Held by Insiders: 1.79%; 11.7%
Shares Held by Institutions: 12.0%; 56.4%

Short sellingIndustry

Short Interest: 928,945; –
Short Interest Change: 54.9%; -0.80%
Days to Cover: 1.00; 5.15

Stock price statisticsIndustry

52-Week High: $2.43; –
52-Week Low: $0.24; –
20-Day Moving Average: $0.61; –
50-Day Moving Average: $0.54; –
200-Day Moving Average: $0.96; –
Average True Range (14): $0.16; –
Price Change (1 Week): 37.0%; -1.15%
Price Change (1 Month): -3.96%; -4.87%
Price Change (3 Months): -32.4%; -21.0%
Price Change (6 Months): -53.7%; -20.6%
Price Change (YTD): -67.1%; -23.6%
Price Change (1 Year): -75.5%; -22.4%
Price Change (3 Years): -60.5%; -29.5%
Price Change (5 Years): -94.8%; -77.9%
Average Volume (10 Days): 1M; –
Average Volume (20 Days): 2M; –
Average Volume (90 Days): 1M; –
Relative Volume: 0.16; 0.70
Relative Strength Index (14): 47.6; 43.4
Volatility (1 Year): 157.9%; 80.1%
Beta (5 Years): 0.97; 1.07

Returns on capitalIndustry

Return on Assets (ROA): -400.7%; -40.6%

Financial positionIndustry

Current Ratio: 0.20; 3.30
Quick Ratio: 0.01; 2.39

EfficiencyIndustry

Profits Per Employee: -$15.46K; -$689.41K
Employee Count: 473; 74
WACC: 9.97%; 10.2%

Income statement (TTM)Industry

Operating Income: -$7.31M; -$21.37M
Pretax Income: -$7.31M; -$12.95M
Net Income: -$7.31M; -$22.35M
EBITDA: -$7.31M; -$17.21M
EPS (Diluted): -$0.27; -$0.76

Balance sheetIndustry

Cash & Short-Term Investments: $100.00K; $68.68M
Net Cash (Debt): $100.00K; $17.76M
Net Cash Per Share: $0.00; $0.80
Equity (Book Value): -$7.43M; $53.89M
Book Value Per Share: -$0.17; $1.50
Tangible Book Value: -$7.43M; $27.13M
Working Capital: -$7.43M; $79.99M

Cash flow (TTM)Industry

Operating Cash Flow: -$16.07M; -$12.38M

Dividends and yieldsIndustry

Earnings Yield: -32.7%; -21.8%
Buyback Yield: 1.59%; -0.76%
Shareholder Yield: 1.59%; 0.00%

Taxes and interestIndustry

Income Tax: $1.63K; $73.00K

Scores and fair valueIndustry

Altman Z-Score: -48.57; 0.23
Piotroski F-Score: 2; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	ESLAW	S&P 500	Difference	ESLAW per year	S&P 500 per year
1 month	+66.9%	-3.0%	+70.0 pts
3 months	+25.8%	-2.8%	+28.6 pts
Year to date	+75.6%	+11.5%	+64.1 pts
1 year	-27.0%	+13.5%	−40.4 pts
3 years	+101.4%	+77.7%	+23.7 pts	+26.3%	+21.1%
5 years	-83.1%	+72.6%	−155.7 pts	-29.9%	+11.5%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

0M ESLAW shares were sold short on Oct 30, 2026, up 0.0% from the previous report. At recent volumes it would take 7.6 days to buy them back. Over the last 20 sessions, 76.1% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	23,732	+0.0%	3,111	7.6
Oct 15, 2026	23,729	-13.7%	820	28.9
Sep 30, 2026	27,511	-6.9%	467	58.9
Sep 15, 2026	29,557	-0.7%	34	869.3
Aug 31, 2026	29,765	-1.3%	251	118.6
Aug 14, 2026	30,142	-8.0%	656	46.0
Jul 31, 2026	32,761	+11.0%	1,118	29.3
Jul 15, 2026	29,509	+6.0%	1,600	18.4
Jun 30, 2026	27,836	+1.5%	630	44.2
Jun 15, 2026	27,436	+4.3%	2,902	9.4
May 29, 2026	26,312	-6.5%	4,059	6.5
May 15, 2026	28,139	+16.1%	2,230	12.6

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?